ArticleEJHaem2025

Safety, Efficacy, and Patient-Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal Hemoglobinuria.

Jun-Ho Jang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.